Investments
8Portfolio Exits
6
Want to inform investors similar to Cormorant Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Cormorant Capital News
Dec 7, 2021
This brings the company's total financing to over $800 million since the company was founded in 2014. This round of financing was led by investors Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc. In addition, there were several new biotech institutional investors well-placed to support the company's mission including ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, and other undisclosed funds. Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Cormorant Capital Investments
8 Investments
Cormorant Capital has made 8 investments. Their latest investment was in Shoreline Biosciences as part of their Series A on April 4, 2021.
Cormorant Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/7/2021 | Series A | Shoreline Biosciences | $43M | Yes | Boxer Capital, BVF Partners, Commodore Capital, Cormorant Capital, Janus Henderson Investors, Kite Pharma, Logos Capital, Stork Capital, and Undisclosed Investors | 4 |
1/9/2021 | Series B | |||||
11/9/2020 | Series D | |||||
10/15/2020 | Series A | |||||
6/5/2020 | Series C - II |
Date | 4/7/2021 | 1/9/2021 | 11/9/2020 | 10/15/2020 | 6/5/2020 |
|---|---|---|---|---|---|
Round | Series A | Series B | Series D | Series A | Series C - II |
Company | Shoreline Biosciences | ||||
Amount | $43M | ||||
New? | Yes | ||||
Co-Investors | Boxer Capital, BVF Partners, Commodore Capital, Cormorant Capital, Janus Henderson Investors, Kite Pharma, Logos Capital, Stork Capital, and Undisclosed Investors | ||||
Sources | 4 |
Cormorant Capital Portfolio Exits
6 Portfolio Exits
Cormorant Capital has 6 portfolio exits. Their latest portfolio exit was VectivBio on April 09, 2021.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
